These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 33983065)

  • 1. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.
    Mahmud R; Rahman MM; Alam I; Ahmed KGU; Kabir AKMH; Sayeed SKJB; Rassel MA; Monayem FB; Islam MS; Islam MM; Barshan AD; Hoque MM; Mallik MU; Yusuf MA; Hossain MZ
    J Int Med Res; 2021 May; 49(5):3000605211013550. PubMed ID: 33983065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
    JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Slandzicki AJ; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Jayaweera D; McCarthy MW; Sulkowski M; Rothman RL; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    JAMA; 2023 Mar; 329(11):888-897. PubMed ID: 36807465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Rothman RL; Jayaweera D; McCarthy MW; Sulkowski M; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    medRxiv; 2022 Dec; ():. PubMed ID: 36561174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
    Wada T; Hibino M; Aono H; Kyoda S; Iwadate Y; Shishido E; Ikeda K; Kinoshita N; Matsuda Y; Otani S; Kameda R; Matoba K; Nonaka M; Maeda M; Kumagai Y; Ako J; Shichiri M; Naoki K; Katagiri M; Takaso M; Iwamura M; Katayama K; Miyatsuka T; Orihashi Y; Yamaoka K;
    Front Med (Lausanne); 2023; 10():1139046. PubMed ID: 37283627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
    Mohan A; Tiwari P; Suri TM; Mittal S; Patel A; Jain A; Velpandian T; Das US; Boppana TK; Pandey RM; Shelke SS; Singh AR; Bhatnagar S; Masih S; Mahajan S; Dwivedi T; Sahoo B; Pandit A; Bhopale S; Vig S; Gupta R; Madan K; Hadda V; Gupta N; Garg R; Meena VP; Guleria R
    J Infect Chemother; 2021 Dec; 27(12):1743-1749. PubMed ID: 34483029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
    ; Naggie S
    medRxiv; 2022 Aug; ():. PubMed ID: 35982669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
    Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
    Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
    de la Rocha C; Cid-López MA; Venegas-López BI; Gómez-Méndez SC; Sánchez-Ortiz A; Pérez-Ríos AM; Llamas-Velázquez RA; Meza-Acuña AI; Vargas-Íñiguez B; Rosales-Galván D; Tavares-Váldez A; Luna-Gudiño N; Hernández-Puente CV; Milenkovic J; Iglesias-Palomares C; Méndez-Del Villar M; Gutiérrez-Dieck GA; Valderrábano-Roldán CG; Mercado-Cerda J; Robles-Bojórquez JG; Mercado-Sesma AR
    BMC Infect Dis; 2022 Dec; 22(1):917. PubMed ID: 36482326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    Hayward G; Yu LM; Little P; Gbinigie O; Shanyinde M; Harris V; Dorward J; Saville BR; Berry N; Evans PH; Thomas NPB; Patel MG; Richards D; Hecke OV; Detry MA; Saunders C; Fitzgerald M; Robinson J; Latimer-Bell C; Allen J; Ogburn E; Grabey J; de Lusignan S; Hobbs FR; Butler CC;
    J Infect; 2024 Apr; 88(4):106130. PubMed ID: 38431155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
    Chaccour C; Casellas A; Blanco-Di Matteo A; Pineda I; Fernandez-Montero A; Ruiz-Castillo P; Richardson MA; Rodríguez-Mateos M; Jordán-Iborra C; Brew J; Carmona-Torre F; Giráldez M; Laso E; Gabaldón-Figueira JC; Dobaño C; Moncunill G; Yuste JR; Del Pozo JL; Rabinovich NR; Schöning V; Hammann F; Reina G; Sadaba B; Fernández-Alonso M
    EClinicalMedicine; 2021 Feb; 32():100720. PubMed ID: 33495752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.
    Biber A; Harmelin G; Lev D; Ram L; Shaham A; Nemet I; Kliker L; Erster O; Mandelboim M; Schwartz E
    Int J Infect Dis; 2022 Sep; 122():733-740. PubMed ID: 35811080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.
    Turner JD; Mand S; Debrah AY; Muehlfeld J; Pfarr K; McGarry HF; Adjei O; Taylor MJ; Hoerauf A
    Clin Infect Dis; 2006 Apr; 42(8):1081-9. PubMed ID: 16575724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of ivermectin in the treatment of Covid-19: A pilot trial.
    Pott-Junior H; Paoliello MMB; Miguel AQC; da Cunha AF; de Melo Freire CC; Neves FF; da Silva de Avó LR; Roscani MG; Dos Santos SS; Chachá SGF
    Toxicol Rep; 2021; 8():505-510. PubMed ID: 33723507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial.
    Abroug H; Maatouk A; Bennasrallah C; Dhouib W; Ben Fredj M; Zemni I; Kacem M; Mhalla S; Nouira S; Ben Belgacem M; Nasri A; Klii R; Loussaief C; Ben Alya N; Bouanene I; Belguith Sriha A
    Trials; 2023 Feb; 24(1):123. PubMed ID: 36803273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.